# Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)

> **NCT03964090** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 48 (actual)

## Conditions studied

- Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma

## Interventions

- **DRUG:** TEDD-R
- **DRUG:** TEDDI-R
- **DRUG:** Ibrutinib
- **DRUG:** Cytarabine
- **DRUG:** Isavuconazole
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT03964090
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-06-27
- **Primary completion:** 2027-07-01
- **Final completion:** 2028-07-01
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03964090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03964090, "Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03964090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*